CWM
REGN icon

Cornerstone Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cornerstone Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-300
Closed -$232K – 775
2026
Q1 		$232K Sell
300
-10
-3% -$7.66K 0.01% 641
2025
Q4 		$239K Buy
+310
New +$211K 0.01% 611
2025
Q1 		– Sell
-310
Closed -$221K – 614
2024
Q4 		$221K Buy
310
+10
+3% +$8.39K 0.01% 539
2024
Q3 		$315K Sell
300
-17
-5% -$18.9K 0.02% 449
2024
Q2 		$333K Buy
317
+17
+6% +$16.5K 0.03% 416
2024
Q1 		$289K Hold
300
– – 0.02% 433
2023
Q4 		$263K Sell
300
-3
-1% -$2.47K 0.02% 436
2023
Q3 		$249K Buy
303
+3
+1% +$2.36K 0.02% 456
2023
Q2 		$216K Sell
300
-90
-23% -$69.4K 0.02% 474
2023
Q1 		$320K Buy
+390
New +$294K 0.03% 363
2022
Q3 		$322K Hold
468
– – 0.04% 334
2022
Q2 		$277K Buy
468
+78
+20% +$50.7K 0.03% 365
2022
Q1 		$272K Sell
390
-14
-3% -$8.86K 0.03% 383
2021
Q4 		$254K Buy
+404
New +$248K 0.02% 435

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cornerstone Wealth Management's REGN Position: Q2 2026 in Review

Cornerstone Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 300 shares — an estimated $232K sold.

Cornerstone Wealth Management first reported a position in REGN in Q4 2021 and held it in 14 quarters. The position peaked at $333K in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cornerstone Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cornerstone Wealth Management sold 300 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $232K.
  • Cornerstone Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 14 quarters.
  • Cornerstone Wealth Management's Regeneron Pharmaceuticals position peaked at $333K in Q2 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cornerstone Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.